Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftolozane-Tazobactam for Pseudomonas Aeruginosa Infections in Hematological Malignancies and HSCT
NCT04673175Phase 4Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Jan 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ceftolozane + tazobactam in Pseudomonas aeruginosa infection, Bacteremia, pneumonia, sponsored by Weill Cornell Medicine. Started Jan 2023; status: terminated.
02
Drugs
ceftolozane + tazobactam
03
Conditions
Pseudomonas aeruginosa infectionBacteremiapneumonia
Beyond the preview
Go deeper on NCT04673175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04673175.